Access to flucytosine for HIV-infected patients with cryptococcal meningitis - An urgent need

South African Medical Journal

Volumn 104, Issue 9, 2014, Pages 594-595

  Govender, Nelesh P ^a   Meintjes, Graeme ^b,c   Banoo, Shabir ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CREATININE; ELECTROLYTE; FLUCYTOSINE; UREA; ANTIFUNGAL AGENT;

BLOOD CELL COUNT; CRYPTOCOCCAL MENINGITIS; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MORTALITY; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ECONOMICS; HEALTH CARE DELIVERY; HEALTH SERVICE; HIV INFECTIONS; MENINGITIS, CRYPTOCOCCAL; MICROBIOLOGY; SOUTH AFRICA; SUPPLY AND DISTRIBUTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; FLUCYTOSINE; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; MENINGITIS, CRYPTOCOCCAL; SOUTH AFRICA;

EID: 84906541174     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.8713     Document Type: Letter

References (10)

1. Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368(14):1291-302. [http://dx.doi.org/10.1056/NEJMc1305981]
2. Govender NP, Roy M, Oladoyinbo S, et al. Phased implementation of screening for cryptococcal disease in South Africa. S Afr Med J 2012;102(12):914-917.[http://dx.doi.org/10.7196/samj.6228]
3. World Health Organization. Rapid Advice-Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. Geneva: WHO, 2011. http://www.who.int/hiv/pub/cryptococcal_disease2011/en/(accessed 25 July 2014).
4. World Health Organization. WHO Model Lists of Essential Medicines. Geneva: WHO, 2014. http://www.who.int/medicines/publications/essentialmedicines/en/(accessed 25 July 2014).
5. Govender NP, Meintjes G, Bicanic T, et al. Guideline for prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. Southern African Journal of HIV Medicine 2013;14(2):76-86. [http://dx.doi.org/10.7196/SAJHIVMED.930]
6. National Institute for Communicable Diseases. GERMS-SA Annual Report 2012. Johannesburg: National Institute for Communicable Diseases, 2012. www.nicd.ac.za/assets/files/2012_GERMS-SA_Annual_Report.pdf (accessed 25 July 2014).
7. Loyse A, Dromer F, Day J, Lortholary O, Harrison T.S. Flucytosine and cryptococcosis: Time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrob Chemother 2013;68(11):2435-2444. [http://dx.doi.org/10.1093/jac/dkt221]
8. Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: Improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis 2013;13(7):629-637. [http://dx.doi.org/10.1016/S1473-3099(13)70078-1]
9. Bicanic T, Wood R, Bekker LG, Darder M, Meintjes G, Harrison T.S. Antiretroviral roll-out, antifungal roll-back: Access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005;5(9):530-531. [http://dx.doi.org/10.1016/S1473-3099(05)70197-3]
10. Loyse A, Bicanic T, Jarvis J.N. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 2013;368(26):2522-2523. [http://dx.doi.org/10.1056/NEJMc1305981#SA1]